CITY OF INDUSTRY, Calif., July 26 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. announced today it has received a $200,000 commitment from Equity Solutions, Inc. for corporate development and identifying merger and acquisition candidates.
The funding commitment entails Equity Solutions to assist with shareholder relations, introduction to other funding sources, building a management team and strategic alliances.
“Equity Solutions will provide U.S. BioDefense with a financial platform to execute our growth strategy,” said David Chin, CEO of U.S. BioDefense. “I am very excited about this partnership and look forward to providing our shareholders with further updates.”
U.S. BioDefense recently announced it had signed a letter of intent to acquire Emergency Disaster Systems, Inc. (EDS), a forerunner in disaster preparedness. The acquisition of EDS will allow the company to expand the Homeland Security division, by focusing on the mitigation, preparedness, response, and recovery from all forms of terrorist attacks and natural disasters.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. U.S. BioDefense, Inc. is focused on transferring, researching, and commercializing groundbreaking technology from Universities, Research Labs, Fortune 500 Companies, and Government Agencies.
About Equity Solutions, Inc.
Equity Solutions, Inc. (www.EquityIRSolutions.com) is a strategic corporate consulting firm focusing on providing resources for generating tangible results for its clients. These services include creating greater shareholder awareness, going public, assistance with merger and acquisitions.
Forward-Looking Statement
This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of management of U.S. BioDefense, Inc., and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other factors affecting the operation of the businesses of U.S. BioDefense, Inc. U.S. BioDefense, Inc. is under no obligation to, and expressly disclaims any such obligation to, update or alter the respective forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact: David Chin U.S. Biodefense, Inc. 626-961-0562 Eddie Cruz Equity Solutions, Inc. info@equityirsolutions.com
U.S. BioDefense, Inc.; Equity Solutions, Inc.
CONTACT: David Chin of U.S. Biodefense, Inc., +1-626-961-0562; or EddieCruz of Equity Solutions, Inc., info@equityirsolutions.com
Web site: http://www.EquityIRSolutions.com//
